This petition was submitted during the 2017-2019 parliament
Rejected petition Make Epidiolex available on prescription for childhood Epilepsy
Epidiolex is a CBD (Cannabidiol) based drug produced by GW Pharmaceuticals in the UK for treating childhood epilepsy that has completed its 3rd stage trials and is just about to be prescribed for the first time in pharmacies in Denver Colorado in the USA
More details
GW’s Epidiolex®
Epidiolex is GW’s lead cannabinoid product candidate and is a proprietary oral solution of pure plant-derived cannabidiol, or CBD. GW’s Epidiolex development is initially concentrating on severe, orphan, early-onset, treatment-resistant epilepsy syndromes including Dravet syndrome, Lennox-Gastaut syndrome (LGS), Tuberous Sclerosis Complex (TSC) and Infantile Spasms (IS).
This petition was rejected
Why was this petition rejected?
It’s about something that the UK Government or Parliament is not directly responsible for.
We can only accept petitions about matters that the UK Government or the House of Commons are responsible for.
The UK Government and Parliament don't licence medicines or advise doctors on what to prescribe.
The European Medicines Agency and the Medicines and Healthcare products Regulatory Agency are responsible for licensing medicines.
The pharmaceutical company applied to EMA for a licence in February 2018.
You can find out more about unlicensed medicines and prescriptions here:
We only reject petitions that don’t meet the petition standards.